From June 1980 through December 1985, 36 high-risk GTT patients received Bagshawe's EMA/CO regimen, 22 as first-line, and 14 as second-line treatment, after primary chemotherapy with CHAMOCA, or cyclic regimen, or MTX-CF. All treated patients were metastatic at the start of treatment with EMA/CO; three showed liver metastases and one brain metastasis. Seventeen patients had a high score, >15. Nineteen patients had histologically confirmed diagnosis of choriocarcinoma. The overall response rate was 86% with 81% survival during a median observation time of 32 months. The median number of courses needed to achieve complete remission was 3 (range 3-7). Toxicity was acceptable, and was less than with CHAMOCA and MAC regimens. Only 1 out of 17 high-risk patients developed drug resistance, and 3 needed urgent surgery. The relapse rate of responders was 19% after a median of 5.5 months. The survival rate of high-risk patients was 88%, of which 76% are alive with no evidence of disease, while 12% have still detectable β-chorionic gonadotrophin. The remission rate in the second-line treatment group was 64%, higher than using other regimens such as MAC or CHAMOCA. In conclusion, we consider EMA/CO to be the best choice for patients with high-risk GTT, because it is effective and well tolerated. In our opinion, the cure rate of high-risk GTT could perhaps be improved by starting trials to establish what salvage treatment to employ after EMA/CO failure and using more aggressive first-line chemotherapy in selected high-risk patients, on the basis of the scoring system. © 1988 Academic Press, Inc. All rights reserved

Bolis, G., Bonazzi, C., Landoni, F., Mangili, G., Vergadoro, F., Zanaboni, F., et al. (1988). EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT). GYNECOLOGIC ONCOLOGY, 31(3), 439-444 [10.1016/S0090-8258(88)80029-5].

EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT)

Landoni F.;Mangioni C.
1988

Abstract

From June 1980 through December 1985, 36 high-risk GTT patients received Bagshawe's EMA/CO regimen, 22 as first-line, and 14 as second-line treatment, after primary chemotherapy with CHAMOCA, or cyclic regimen, or MTX-CF. All treated patients were metastatic at the start of treatment with EMA/CO; three showed liver metastases and one brain metastasis. Seventeen patients had a high score, >15. Nineteen patients had histologically confirmed diagnosis of choriocarcinoma. The overall response rate was 86% with 81% survival during a median observation time of 32 months. The median number of courses needed to achieve complete remission was 3 (range 3-7). Toxicity was acceptable, and was less than with CHAMOCA and MAC regimens. Only 1 out of 17 high-risk patients developed drug resistance, and 3 needed urgent surgery. The relapse rate of responders was 19% after a median of 5.5 months. The survival rate of high-risk patients was 88%, of which 76% are alive with no evidence of disease, while 12% have still detectable β-chorionic gonadotrophin. The remission rate in the second-line treatment group was 64%, higher than using other regimens such as MAC or CHAMOCA. In conclusion, we consider EMA/CO to be the best choice for patients with high-risk GTT, because it is effective and well tolerated. In our opinion, the cure rate of high-risk GTT could perhaps be improved by starting trials to establish what salvage treatment to employ after EMA/CO failure and using more aggressive first-line chemotherapy in selected high-risk patients, on the basis of the scoring system. © 1988 Academic Press, Inc. All rights reserved
Articolo in rivista - Articolo scientifico
Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Female; Humans; Hydroxyurea; Methotrexate; Middle Aged; Pregnancy; Pregnancy Complications, Neoplastic; Trophoblastic Neoplasms; Uterine Neoplasms; Vincristine
English
439
444
6
Bolis, G., Bonazzi, C., Landoni, F., Mangili, G., Vergadoro, F., Zanaboni, F., et al. (1988). EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT). GYNECOLOGIC ONCOLOGY, 31(3), 439-444 [10.1016/S0090-8258(88)80029-5].
Bolis, G; Bonazzi, C; Landoni, F; Mangili, G; Vergadoro, F; Zanaboni, F; Mangioni, C
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/264983
Citazioni
  • Scopus 103
  • ???jsp.display-item.citation.isi??? 92
Social impact